AVERROES APIXABAN PDF

0 Comments

In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.

Author: Ketaur Kigagami
Country: Estonia
Language: English (Spanish)
Genre: Technology
Published (Last): 15 August 2013
Pages: 335
PDF File Size: 12.21 Mb
ePub File Size: 16.10 Mb
ISBN: 704-8-55887-726-1
Downloads: 33647
Price: Free* [*Free Regsitration Required]
Uploader: Tojashakar

The AVERROES Trial – Clinical Implications

Patients were eligible if they were 50 years of age or older and if they had atrial fibrillation that had been documented in the 6 months prior to enrollment or by lead electrocardiography on the day of screening. A serious bleeding event during VKA therapy; 4. Thus, a clear superiority of apixaban over aspirin was shown in terms of efficacy, with comparable safety.

Analyses are to time of first event. Other characteristics indicating risk of stroke too low to warrant treatment with VKAs; All these reasons can be grouped in three broad categories: Dabigatran versus warfarin in patients with atrial fibrillation.

Related Posts  CONCEPTO DE ANTIDERIVADA PDF

Based on the indirect comparison with ACTIVE A, one should conclude that apixaban is, at the time of writing, the best alternative to aspirin ever found in patients deemed unsuitable for VKAs. Statistics presented where given by the authors. Yet, these proportions reflect the current underuse of VKAs in multiple registries. Dual therapy decreased rates of major vascular events at cost of increased major bleeding. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

The primary outcome was stroke or systemic embolism. Apxiaban reasons that VKA therapy was unsuitable for the patient had to be documented in the study case report forms. AVERROES on the other hand has shown that the new oral anti-Xa inhibitor apixaban is xpixaban to aspirin in terms of efficacy, with surprisingly similar safety. Sign in to My ESC.

Views Read View source View history. Apixaban is, at the time of writing, the best alternative to aspirin in patients deemed unsuitable for vitamin K antagonists. One may question each of these choices: N Engl J Med Apixaban is a novel oral anticoagulant that inhibits factor Xa.

AVERROES – Wiki Journal Club

The median duration of follow-up was 1. Its role in prevention of stroke in patients unsuitable for VKA therapy, but maintained on aspirin therapy, was unknown. Retrieved from ” http: Eur Heart J ; J Am Coll Cardiol ; This proportion was similar for both academic and community hospitals. Presented as apixaban vs.

Related Posts  DET MEDICINEREDE MENNESKE PDF

Assessment that patient would be unable or unlikely to adhere to restrictions averroez factors such as alcohol and diet; Concurrent medications that could alter activity of VKAs; 8. Usable articles Cardiology Neurology. ESC sub specialties communities.

Did you know that your browser is out of date? With a mean follow-up of 1. There were 11 intracranial bleeds on apixaban and 13 on aspirin apixaban 1. To reduce the burden of cardiovascular disease. There were 51 primary outcome events in those randomised to apixaban 1.

The AVERROES Trial – Clinical Implications

Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. In addition, patients could not be receiving VKA therapy, either because it had been demonstrated unsuitable in their case or because it was expected to be unsuitable. It has multiple theoretical benefits over Avegroes therapy including less intensive monitoring and fewer drug interactions.